Due to lack of inclusion of clean needles in the prevention package on trial, results will not be accepted and this is because some procedures that qualify acceptable results were not followed.
I feel that in most trials , stakeholder engagement is not given a priority until a problem arise then we usually realize and go back to find out what was not done accordingly and in most cases is lack of GPP implementation.
With what i have learned with the GPP team, it is very clear that the base stakeholder engagement is very important to create a safe fall back and back up if anything changes or goes wrong in the process of study implementation.
This help the community in return to trust researchers and their teams for even future studies. However, in this case the trust was lost on both results and trial itself and eventually it might be difficult to come back with any trial in the same environment/community.
GPP/stakeholder engagement should be given a place in any trial from the design of a study up to long after a study is implemented
